This review suggests that finasteride is well-tolerated and potentially more effective than other treatments for hirsutism, with results confirmed by other studies.
55 citations
,
August 2008 in “Reviews in endocrine and metabolic disorders”
This review discusses clinical, hormonal, and genetic aspects of nonclassic adrenal hyperplasia and reports no new findings; the condition is highlighted as a potential cause of premature adrenarche and other symptoms in young people.
11 citations
,
February 2008 in “British journal of nursing”
This article reviews idiopathic hirsutism, focusing on its definition, diagnosis, causes, and treatment options, without presenting new clinical findings.
December 2024 in “Journal of Clinical Research in Pediatric Endocrinology”
This study explains that congenital adrenal hyperplasia due to 21-hydroxylase deficiency presents as a continuous phenotype and involves symptoms ranging from virilization to accelerated growth in children, with diagnosis relying on clinical, biochemical, and genetic evaluation.
The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.
The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.
A trans woman is experiencing hair loss and is considering treatments like cyproterone, dutasteride, and oral minoxidil. She is concerned about potential hair growth on her face, chest, or legs due to minoxidil.
Men discussing hair loss treatments, including bicalutamide, cyproterone acetate, dutasteride, minoxidil, and RU58841. They share experiences and concerns about side effects like infertility, liver health, and feminization.
A 35-year-old male uses topical minoxidil, spironolactone, and microneedling for hair loss, with spironolactone prescribed based on a DNA test indicating poor response to finasteride and dutasteride. Despite concerns about the test's validity and spironolactone's side effects, he reports stable or improved hair condition and no low testosterone symptoms.